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Background: Lesions deferred revascularization following fractional ﬂow reserve
(FFR) assessment have a low risk of adverse cardiac events. The variability in
risk for deferred lesion intervention (DLI) has not been evaluated previously. The
aim was to develop a prediction model to estimate the one-year risk of DLI
in coronary lesions where revascularization was not performed following FFR
assessment.
Methods: A prediction model for DLI was developed from a cohort of 721 patients
with 882 coronary lesions where revascularization was deferred based on
FFR between 10/2002 and 7/2010. DLI was deﬁned as any revascularization of
a lesion previously deferred following FFR. The ﬁnal model for DLI was developed
using stepwise Cox regression, and internally validated and calibrated using
bootstrapping techniques. An algorithm was constructed to predict the one-year risk
of DLI.
Results: During a mean (SD) follow-up period of 4.0  2.3 years, 18% of
lesions deferred after FFR underwent DLI; the one-year incidence of DLI was 5%.
Besides FFR values, the ﬁnal Cox model included several predictors of DLI (current
or former smoking, history of coronary artery disease [CAD] or prior PCI,
and multivessel CAD), and two variables negatively associated with DLI (age
and creatinine). The c statistic for the DLI prediction model was 0.66 (95% CI
0.61-0.70).
Conclusions: Patients deferred revascularization based on FFR have variation in
their risk for DLI. A clinical prediction model consisting of 5 clinical variables and
the FFR value can help predict the risk of DLI in the ﬁrst year following FFR
assessment.
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Golden Jubilee National Hospial, Glasgow, United Kingdom
Background: Invasive management guided by coronary angiography is the stan-
dard of care in NSTEMI. We hypothesized that functional assessment of coronary
stenosis severity with fractional ﬂow reserve (FFR) would have additive diagnostic,
clinical and health economic utility, as compared to angiography-guided standard
care.
Methods: A prospective multicenter randomized double-blind controlled trial in acute
NSTEMI patients with 1 coronary stenosis 30% severity (threshold for FFR
measurement) in culprit and non-culprit lesions. Patients were randomized immedi-
ately after coronary angiography to the FFR-guided group or angiography-guided
group. The study design is shown in Figure 1. The primary outcome is the between-
group difference in the proportion of patients allocated to medical management
compared to revascularization. Secondary outcomes include health outcomes, quality
of life, and healthcare costs. The minimum/average follow-up periods are 6 & 18
months, respectively.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrResults: 350 patients were randomized between Oct 2011-May 2013 in 6 UK
hospitals. The participant characteristics are: mean  SD age 6015 years, 74% men,
14% treated diabetes, 8% prior PCI and 10% prior MI. The median (IQR) time from
the index event to the initial angiogram was 3.0(2.0,6.0) days. The median (range)
GRACE Score was 180 (8,269). On average each patient had 1.90.8 angio-
graphically diseased coronary arteries (left main 10%, RCA 58%, LAD/Diagonal
54%, Cx/OM 64%).
Conclusions: The FAMOUS NSTEMI population has high risk characteristics and
differs in several ways from the FAME trial participants.Percutaneous Treatment of Mitral Valve Disease
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Background: Reverse remodeling of the left ventricle (LV) and left atrium (LA) is
a desirable outcome after mitral valve repair (MVR) for signiﬁcant mitral regurgitation
(MR). Using data from the EVEREST II randomized trial, we compared the extent of
left-sided chamber reverse remodeling between the percutaneous and surgical mitral
repair cohorts.
Methods: The EVEREST II trial is a prospective, multicenter, randomized, non-
blinded evaluation of the percutaneous MitraClip system compared in 2:1 fashion to
surgical MVR in the setting of moderate to severe MR. Four year follow up echo-
cardiographic data was available for 85 individuals with percutaneous repair (PR) and
42 with surgical repair (SR). Successful repair was deﬁned as 2+ residual MR.
Results: Baseline characteristics and LV and LA dimensions were similar in PR and
SR groups except for a greater proportion of history of heart failure in the PR group.
At 4 years, 73% (62/85) of the PR group and 93% (39/42) of the SR group had  2+
MR. LV systolic and diastolic dimensions were signiﬁcantly reduced in both groups at
4 years, although the SR group had signiﬁcantly more reverse remodeling (Table 1,acts/ORAL/Percutaneous Treatment of Mitral Valve Disease B27
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Sp ¼ <0.001). Reduction in LV volumes was seen in both functional and degenerative
MR subtypes. LA volumes decreased an average of 29 ml (p ¼0.009) after successful
SR, but LA volumes were only reduced signiﬁcantly in the PR group when residual
MR severity was  1+ (reduction of 14 ml, p¼0.0016). (Table 1).
Conclusions: Favorable LV remodeling occurred after successful PR, however
improvements were less robust compared to SR at 4 years. LA volumes improved
signiﬁcantly after successful SR, but only after PR when residual MR was 1+.
Further study should inform whether the degree of reverse remodeling impacts long-
term clinical outcomes and MitraClip durability.P
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All £2+ LVEDVI
(ml/m2)
15033
(61)
12134
(59)
-2929 <0.001 16247
(39)
11342
(35)
-5132 <0.001 <0.001
LVESVI
(ml/m2)
6122
(61)
5224
(59)
-819 0.0018 6128
(39)
4929
(35)
-1317 <0.001 0.2
LA
volume
(ml)
7824
(59)
7326
(59)
-523 0.11 8133
(37)
5220
(33)
-2822 <0.001 <0.001
LVEF% 609.0
(61)
589
(59)
-28 0.06 639
(39)
5811
(35)
-49 0.009 0.2
All £1+ LVEDVI
(ml/m2)
15135
(28)
11426
(28)
-3426 <0.001 15844
(35)
10633
(31)
-5332 <0.001 0.019
LVESVI
(ml/m2)
6425
(28)
4817
(28)
-1517 <0.001 5620
(35)
4422
(31)
-1316 <0.001 0.61
LA
volume
(ml)
7920
(28)
6720
(27)
-1420 0.0016 8134
(33)
4919
(31)
-2921 <0.001 0.009
LVEF % 5811
(28)
5810
(28)
110 0.72 656
(35)
6010
(29)
-510 0.0085 0.035
basal post ES post nitro
basal after
Clip
Post ES
after Clip
average Peak gradient
(mmHg)
5627 13423 8428 106 229
patient #1 PP-gradient 36.0 136.0 55.0 3.0 19.0
patient #2 PP-gradient 75.0 150.0 120.0 7.0 35.0
patient #3 PP-gradient 84.0 150.0 90.0 13.0 16.0
patient #4 PP-gradient 30.0 100.0 70.0 17.0 18.0
average Mean gradient
(mmHg)
4113 8933 6121 135 217
SAM ++ +++ +++ 0 +
MR (grade) 2.60.25 3.00 3.00 0.50.4 0.630.25
patient #1 mean
transmitral gradient
3.0 n.a. n.a. 5.0 n.a.
patient #2 mean
transmitral gradient
2.0 n.a. n.a. 3.0 n.a.
patient #3 mean
transmitral gradient
3.0 n.a. n.a. 3.0 n.a.
patient #4 mean
transmitral gradient
3.0 n.a. n.a. 6.0 n.a.TCT-86
The 2011-12 Pilot European Sentinel Registry of Percutaneous Edge-to-Edge
Mitral Valve Repair: In-hospital results and mid-term follow up of 587 patients
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Background: Edge-to-edge percutaneous mitral valve repair has emerged as an
alternative to surgery in high-risk patients. However, data with regard to its safety and
efﬁcacy in real-world patients are still scarce. The aim of this prospective multina-
tional registry is to present a real-world overview of MitraClip use focusing on patient
characteristics, clinical indication, technique, in-hospital and mid-term outcome.
Methods: The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective
independent consecutive collection of individual patient data entered into a web-based
case record form (CRF).
Results: A total of 587 patients (mean age 74.79.5 years, 64.1 % male) underwent
MitraClip implantation between January 2011 and December 2012 in 25 centres of 8
European countries. The prevalent etiology was functional MR (FMR; 414 patients,
70.5%) while 150 patients (25.5%) were diagnosed as having degenerative MR
(DMR), with the remaining patients (23, 4.0%) classiﬁed as mixed aetiology or MR of
unknown origin.Logistic EuroSCORE was high (19.916.0%). Successful deploy-
ment of at least 1 clip was achieved in 95.9% of patients, with a trend to higher
implantation success in the FMR group (p¼0.087). Acute procedural success was high
(97.3%) and equivalent between groups (p¼1.000). One clip was implanted in the
majority of cases (60.7%), two clips were implanted in 35.9% of cases and a small
minority received 3 or more clips (3.4%). Patients with DMR tended to receive
a greater number of clips (2 clips implanted in 43.5% of patients with DMR vs.
37.4% of patients with FMR, p¼0.191) than those with functional mitral regurgitation.
Echocardiograms prior to discharge showed a marked reduction in mitral insufﬁciency
to 2+ in 98.2% of patients, with equivalence between groups. In-hospital mortality
was low (2.0%) and without signiﬁcant differences between groups, although DMR
group had a trend to higher mortality. Clinical and echo follow-up data at 6-12 month
will be available at the time of presentation.B28 JACC Vol 62/18/Suppl B j October 27–November 1, 2013Conclusions: this truly independent and contemporary registry of MitraClip
implantation shows that the technique is effective and is associated with low
complication rate.
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Targeting systolic anterior motion and left ventricular outﬂow tract obstruction
in hypertrophic obstructed cardiomyopathy with a MitraClip
Ulrich Schaefer1, Christian Frerker1, Felix Kreidel1, Karl-Heinz Kuck1
1Asclepios Clinics St. Georg, Hamburg, Germany
Background: Hypertrophic obstructive cardiomyopathy (HOCM) with left ventric-
ular outﬂow tract obstruction frequently involves a systolic anterior motion (SAM) of
the anterior mitral leaﬂet. We hypothesized, that SAM could be a new target for
MitraClip therapy.
Methods: Four patients with HOCM were chosen for MitraClip therapy, due to
signiﬁcant SAM with subsequent mitral regurgitation. Invasive hemodynamic studies
(right heart catheterization, simultaneous transaortic pressure recording, administra-
tion of nitroglycerin) before and after MitraClip implantation in addition to 6 weeks
follow-up were performed.
Results: MitraClip implantation was successfully performed with signiﬁcant reduc-
tion of mitral regurgitation and SAM in all patients. Basal peak gradients (before Clip:
5627 mmHg; after clip: 106 mmHg) as well as provoked pressure gradients
(before clip: 13423 mmHg; after clip: 218 mmHg) were signiﬁcantly reduced after
MitraClip. Right heart catheterization data did not reveal major changes. At 6-weeks
follow-up, all patients presented in a persistent improved clinical state (NYHA class I-
II) with insigniﬁcant residual MR and continuously reduced LVOT gradients.
Conclusions: This is the ﬁrst catheter-based study targeting primarily a SAM in
HOCM to reduce LVOT obstruction. The results prove the concept, that SAM is more
than an epiphenomenon in HOCM. Thus, SAM-induced obstruction might be
a valuable target for the MitraClip.TCT-88
Outcomes of Cardiac Surgery are Preserved Following the MitraClip Procedure.
Alfredo Trento1, Wen Loong Yeow1, Takashi Matsumoto1, Asma Hussaini1,
Swaminatha V. Gurudevan1, Takahiro Shiota1, Saibal Kar1
1Cedars-Sinai Medical Center, Los Angeles, CA
Background: Transcatheter mitral valve repair with the MitraClip is a safe procedure
for severe mitral regurgitation (MR). A reported higher mitral valve replacement rate
following the MitraClip resulted in an overstated complexity of subsequent surgery
and its implications on patient outcomes. This study will review the outcomes of
cardiac surgery following MitraClip procedure.
Methods: Of the 157 consecutive patients that underwent the MitraClip procedure in
our center, 16 (10%) required cardiac surgery. These patients (mean 6712 years old,
7 (44%) women) with Society of Thoracic Surgeons mortality score of 0.5 to 17.1%
were reviewed in regards to their operative details and outcomes. The mean implant
duration was 12.5 months (range 14 days to 75 months).
Results: No patient required urgent cardiac surgery for failed MitraClip procedure. Of
the 9 patients with degenerative MR, 8 were repaired and 1 had a replacement for
MitraClip endocarditis. Robotic assisted repair occurred in one patient that had no
implanted clip whilst 2 had one clip, and 3 had two clips; the implant duration ranged
from 2.5 months to 6.3 years. Of the 7 patients with functional MR, 5 had replacement
and 2 required heart transplantation for severe heart failure. There was no operativej TCT Abstracts/ORAL/Percutaneous Treatment of Mitral Valve Disease
